PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone
* To evaluate the overall tumor response rate in subjects with metastatic hormone refractory prostate cancer
* To evaluate PSA (tumor marker) response rate
* To evaluate safety
Prostatic Neoplasms
DRUG: ARD6562, Docetaxel
Overall tumor response rate by Response Evaluation Criteria in Solid Tumor (RECIST)
Overall response rate by modified WHO criteria, PSA response rate, safety
* To evaluate the overall tumor response rate in subjects with metastatic hormone refractory prostate cancer
* To evaluate PSA (tumor marker) response rate
* To evaluate safety